The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical evaluation of 64Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor–positive breast cancer.
 
Takeshi Usui
Speakers' Bureau - Kyowa Kirin
Research Funding - LinqMed (Inst)
 
Tomohiro Miyake
Stock and Other Ownership Interests - Abbvie
Speakers' Bureau - AstraZeneca Japan
Research Funding - LinqMed (Inst)
 
Tadashi Watabe
Honoraria - Bayer; Eisai; Janssen; NMP; PDRadiopharma; Siemens; Sumitomo Heavy Industries; Takeda
Research Funding - Alpha fusion
 
Hiroki Katoh
Research Funding - GE Healthcare
 
Kaori Abe
No Relationships to Disclose
 
Nanae Masunaga
Honoraria - Japan Society of preventive medicine; Osaka medical association
Speakers' Bureau - Daiichi Sankyo; Nippon Kayaku
 
Chieko Mishima
No Relationships to Disclose
 
Masami Tsukabe
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD
 
Tetsuhiro Yoshinami
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin International; Lilly Japan; MSD; MSD; Pfizer
 
Yoshiaki Sota
No Relationships to Disclose
 
Tomonori Tanei
No Relationships to Disclose
 
Masafumi Shimoda
Speakers' Bureau - Chugai Pharma; MSD; Pfizer
 
Kenzo Shimazu
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Pfizer; Sysmex
Research Funding - AstraZeneca Japan (Inst); Gilead Sciences (Inst); MSD (Inst); Ono Yakuhin; Pfizer (Inst)